Halted gene therapy study raises questions for AMN patients
NCT ID NCT05394064
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a gene therapy called SBT101 for adrenomyeloneuropathy (AMN), a rare nerve disease that causes walking difficulties. Eight adults received either the therapy or a sham procedure. The study was terminated early, so we have limited data on safety and effectiveness. Researchers were measuring side effects and changes in walking ability over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SBT101 gene therapy (AAV9-ABCD1)
- What this could lead to
- If successful, this could point toward a treatment that slows or stops the progression of adrenomyeloneuropathy, a rare and disabling nerve disease.
- What could go wrong
- The trial was terminated early with only 8 participants, so results are very limited. Gene therapies can have unexpected side effects, and it is unclear if SBT101 will work in humans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amsterdam UMC
Amsterdam, Netherlands
-
University of Massachusetts Chan Medical School
Worcester, Massachusetts, 01655, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.